{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:47:40Z","timestamp":1785365260271,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor proliferation and immune infiltration are key determinants of breast cancer biology, yet their prognostic value in the advanced setting remains incompletely defined. We evaluated the clinical relevance of tumor\u2011infiltrating lymphocytes (TILs) and four cell cycle regulation biomarkers\u2014Ki67, MCM2, Cyclin A, and PHH3\u2014across major breast cancer subtypes in a contemporary real\u2011world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of the outcomes of 398 patients with advanced breast cancer treated between 2020 and 2024. Clinicopathological variables were compared across HER2\u2212\/HR+, HER2+, and triple\u2011negative breast cancer (TNBC). Progression\u2011free survival (PFS) was assessed using Kaplan\u2013Meier analysis and log\u2011rank tests. Multivariable polytomous logistic regression identified factors associated with PFS\u2009&lt;\u20092 years. Subtype\u2011specific associations between TILs and PFS\u2009&gt;\u20092 years were evaluated using multivariable Cox models adjusted for age, ECOG status, tumor grade, and prior therapies. Additional Cox regression models assessed predictors of overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low TIL density was independently associated with early progression (RRR 2.28, 95% CI 1.19\u20134.03). Proliferation markers showed consistent associations with PFS: elevated Ki67, MCM2, Cyclin A, and PHH3 each correlated with shorter survival, with MCM2 showing the strongest effect. TIL\u2013PFS associations were subtype\u2011dependent. In HR+\/HER2\u2009\u2212\u2009disease, high TILs were linked to shorter PFS (HR 2.27, 95% CI 1.18\u20134.02), whereas in TNBC, low TILs predicted markedly worse outcomes (HR 2.33, 95% CI 1.88\u20132.86). TIL levels were not prognostic in HER2\u2009+\u2009disease. Across all subtypes, high expression of Ki67, MCM2, Cyclin A, and PHH3 was significantly associated with reduced OS in multivariable models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Subtype\u2011specific immune infiltration and elevated proliferation activity are key predictors of disease trajectory in advanced breast cancer. TILs carry divergent prognostic meaning across subtypes, whereas proliferation markers consistently identify high\u2011risk disease. Integrating immune and proliferative biomarkers may enhance risk stratification and guide treatment tailoring, particularly within TNBC and hormonally driven tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07991-9","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:23:16Z","timestamp":1780586596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of baseline tumor-infiltrating lymphocytes and cell-cycle regulation markers on prognosis and mortality in patients with advanced breast cancer according to tumor characteristics and treatment type: an observational study"],"prefix":"10.1007","volume":"217","author":[{"given":"Sauli","family":"Vuoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Saari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Lahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Narasimha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Reinikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"8","key":"7991_CR1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/onc.2009.416","volume":"29","author":"F Pag\u00e8s","year":"2010","unstructured":"Pag\u00e8s F, Galon J, Dieu\u2013Nosjean M\u2013C, Tartour E, Saut\u00e8s\u2013Fridman C (2010) Fridman W\u2013H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29(8):1093\u20131102. https:\/\/doi.org\/10.1038\/onc.2009.416","journal-title":"Oncogene"},{"issue":"10","key":"7991_CR2","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML (2016) Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol 2(10):1354\u20131360. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1061","journal-title":"JAMA Oncol"},{"key":"7991_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41523-025-00760-9","volume":"11","author":"B Taurelli Salimbeni","year":"2025","unstructured":"Taurelli Salimbeni B, Giudici F, Pescia C, Berton Giachetti PPM, Scafetta R, Zagami P, Marra A, Trapani D, Esposito A, Scagnoli S, Cerbelli B, Botticelli A, Munzone E, Fusco N, Criscitiello C, Curigliano G (2025) Prognostic impact of tumor-infiltrating lymphocytes in HER2\u2009+\u2009metastatic breast cancer receiving first-line treatment. NPJ Breast Cancer 11:41. https:\/\/doi.org\/10.1038\/s41523-025-00760-9","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"7991_CR4","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","volume":"26","author":"MV Dieci","year":"2015","unstructured":"Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A (2015) Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 26(8):1698\u20131704. https:\/\/doi.org\/10.1093\/annonc\/mdv239","journal-title":"Ann Oncol"},{"issue":"7","key":"7991_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung SCY, Rimm DL et al (2021) Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 113(7):808\u2013819. https:\/\/doi.org\/10.1093\/jnci\/djaa201","journal-title":"J Natl Cancer Inst"},{"key":"7991_CR6","doi-asserted-by":"publisher","first-page":"17989","DOI":"10.1038\/s41598-017-17845-6","volume":"7","author":"IM Lazar","year":"2017","unstructured":"Lazar IM, Hoeschele I, de Morais J, Tenga MJ (2017) Cell cycle model system for advancing cancer biomarker research. Sci Rep 7:17989","journal-title":"Sci Rep"},{"issue":"2","key":"7991_CR7","doi-asserted-by":"publisher","first-page":"e0172324","DOI":"10.1371\/journal.pone.0172324","volume":"12","author":"Y Pan","year":"2017","unstructured":"Pan Y, Yuan Y, Liu G, Wei Y (2017) P53 and Ki\u201367 as prognostic markers in triple\u2013negative breast cancer patients. PLoS ONE 12(2):e0172324. https:\/\/doi.org\/10.1371\/journal.pone.0172324","journal-title":"PLoS ONE"},{"key":"7991_CR8","doi-asserted-by":"publisher","first-page":"30091","DOI":"10.1038\/srep30091","volume":"6","author":"R\u2013X Wang","year":"2016","unstructured":"Wang R\u2013X, Chen S, Jin X, Shao Z\u2013M (2016) Value of Ki\u201367 expression in triple\u2013negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci Rep 6:30091","journal-title":"Sci Rep"},{"issue":"1","key":"7991_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105\u2013113. https:\/\/doi.org\/10.1200\/JCO.2009.23.7370","journal-title":"J Clin Oncol"},{"issue":"7","key":"7991_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JPA, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C (2013) Prognostic and predictive value of tumor\u2013infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node\u2013positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin\u2013based chemotherapy: BIG 02\u201398. J Clin Oncol 31(7):860\u2013867. https:\/\/doi.org\/10.1200\/JCO.2011.41.0902","journal-title":"J Clin Oncol"},{"issue":"27","key":"7991_CR11","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959\u20132966. https:\/\/doi.org\/10.1200\/JCO.2013.55.0491","journal-title":"J Clin Oncol"},{"issue":"10","key":"7991_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/modpathol.2016.109","volume":"29","author":"C Denkert","year":"2016","unstructured":"Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago\u2013Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Salgado R (2016) Standardized evaluation of tumor\u2013infiltrating lymphocytes in breast cancer: results of the ring studies of the International Immuno\u2013Oncology Biomarker Working Group. Mod Pathol 29(10):1155\u20131164. https:\/\/doi.org\/10.1038\/modpathol.2016.109","journal-title":"Mod Pathol"},{"issue":"1","key":"7991_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb\u2013Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer J\u2013U, Karn T, Pfitzner BM, K\u00fcmmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S (2018) Tumour\u2013infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-X.","journal-title":"Lancet Oncol"},{"issue":"7","key":"7991_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S et al (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37(7):559\u2013569. https:\/\/doi.org\/10.1200\/JCO.18.01010","journal-title":"J Clin Oncol"},{"issue":"2","key":"7991_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/annonc\/mdv571","volume":"27","author":"G Pruneri","year":"2016","unstructured":"Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, Colleoni AM, Goldhirsch A, Viale G (2016) Clinical validity of tumor\u2013infiltrating lymphocytes analysis in patients with triple\u2013negative breast cancer. Ann Oncol 27(2):249\u2013256. https:\/\/doi.org\/10.1093\/annonc\/mdv571","journal-title":"Ann Oncol"},{"issue":"3","key":"7991_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P (2019) Pembrolizumab monotherapy for previously untreated, PD\u2013L1\u2013positive, metastatic triple\u2013negative breast cancer: cohort B of the phase II KEYNOTE\u2013086 study. Ann Oncol 30(3):405\u2013411. https:\/\/doi.org\/10.1093\/annonc\/mdy518","journal-title":"Ann Oncol"},{"issue":"8","key":"7991_CR17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu\u2013Lehtinen P\u2013L, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor\u2013infiltrating lymphocytes are prognostic in triple\u2013negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25(8):1544\u20131550. https:\/\/doi.org\/10.1093\/annonc\/mdu112","journal-title":"Ann Oncol"},{"key":"7991_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","volume":"7","author":"K El Bairi","year":"2021","unstructured":"El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, Ribeiro de Freitas J, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu S-W, Lien H-C, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen I-C, The International Immuno\u2013Oncology Biomarker Working Group (2021) The tale of TILs in breast cancer: A report from The International Immuno\u2013Oncology Biomarker Working Group. npj Breast Cancer 7:150","journal-title":"npj Breast Cancer"},{"key":"7991_CR19","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3389\/fimmu.2017.01412","volume":"8","author":"C Solinas","year":"2017","unstructured":"Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vit\u00f3ria J, Richard F, Migliori E, No\u00ebl G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart\u2013Gebhart M, Willard\u2013Gallo K (2017) Immune checkpoint molecules on tumor\u2013infiltrating lymphocytes and their association with tertiary lymphoid structures in human breast cancer. Front Immunol 8:1412. https:\/\/doi.org\/10.3389\/fimmu.2017.01412","journal-title":"Front Immunol"},{"issue":"1","key":"7991_CR20","first-page":"165","volume":"26","author":"YA Civil","year":"2026","unstructured":"Civil YA, Purcell ND, de Vries R, Oei AL, Thijssen VLJL, de Gruijl TD, Slotman BJ, Schneiders FL, van den Bongard HJGD (2026) Prognostic value of tumor\u2013infiltrating lymphocytes in breast cancer patients treated with radiotherapy: A systematic review of literature. Breast Cancer Res Treat 26(1):165\u2013178e1","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7991_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"issue":"6","key":"7991_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/pap.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international Immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311\u2013335. https:\/\/doi.org\/10.1097\/pap.0000000000000161","journal-title":"Adv Anat Pathol"},{"key":"7991_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00428-016-1923-2","volume":"468","author":"T T\u0151k\u00e9s","year":"2016","unstructured":"T\u0151k\u00e9s T, T\u0151k\u00e9s A\u2013M, Szentm\u00e1rtoni G, Kiszner G, Madaras L, Kulka J, Kren\u00e1cs T, Dank M (2016) Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer. Virchows Arch 468:675\u2013686. https:\/\/doi.org\/10.1007\/s00428-016-1923-2","journal-title":"Virchows Arch"},{"issue":"11","key":"7991_CR24","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/bjc.2012.167","volume":"106","author":"HR Ali","year":"2012","unstructured":"Ali HR, Dawson S\u2013J, Blows FM, Provenzano E, Pharoah PD, Caldas C (2012) Aurora kinase A outperforms Ki67 as a prognostic marker in ER\u2013positive breast cancer. Br J Cancer 106(11):1798\u20131806. https:\/\/doi.org\/10.1038\/bjc.2012.167","journal-title":"Br J Cancer"},{"key":"7991_CR25","doi-asserted-by":"crossref","unstructured":"T\u0151k\u00e9s A\u2013M, Sz\u00e1sz AM, Geszti F, Luk\u00e1cs LV, Kenessey I, Tur\u00e1nyi E, Meggyesh\u00e1zi N, Moln\u00e1r IA, Fillinger J, Solt\u00e9sz I, B\u00e1lint K, Hanz\u00e9ly Z, Arat\u00f3 G, Szendr\u00f6i M, Kulka J (2015) Expression of proliferation markers Ki67, cyclin A, geminin and aurora\u2013kinase A in primary breast carcinomas and corresponding distant metastases. J Clin Pathol 68(4):274\u2013282. https:\/\/jcp.bmj.com\/content\/68\/4\/274.short","DOI":"10.1136\/jclinpath-2014-202607"},{"issue":"7","key":"7991_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm A\u2013V, Pan H, Penault\u2013Llorca FM, Polley M\u2013Y, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF (2021) Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 113(7):808\u2013819. https:\/\/doi.org\/10.1093\/jnci\/djaa201","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"7991_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jcp.2005.030452","volume":"59","author":"C Bossard","year":"2006","unstructured":"Bossard C, Jarry A, Colombeix C, Bach\u2013Ngohou K, Moreau A, Loussouarn D, Mosnier J\u2013F, Laboisse CL (2006) Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer\u2013assisted determination of mitotic index. J Clin Pathol 59(7):706\u2013710. https:\/\/doi.org\/10.1136\/jcp.2005.030452","journal-title":"J Clin Pathol"},{"issue":"6","key":"7991_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/sj.bjc.6604924","volume":"100","author":"M Loddo","year":"2009","unstructured":"Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, Young J, El\u2013Sheikh S, Falzon M, Eward KL, Prevost T, Sainsbury R, Stoeber K, Williams GH (2009) Cell\u2013cycle\u2013phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 100(6):959\u2013970. https:\/\/doi.org\/10.1038\/sj.bjc.6604924","journal-title":"Br J Cancer"},{"issue":"7","key":"7991_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.0101","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix\u2013Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu\u2013Lehtinen P\u2013L, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S (2019) Tumor\u2013infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early\u2013stage triple\u2013negative breast cancers. J Clin Oncol 37(7):559\u2013569. https:\/\/doi.org\/10.1200\/JCO.18.0101","journal-title":"J Clin Oncol"},{"issue":"11","key":"7991_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple\u2013negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"7991_CR31","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15\u2013year survival: an overview of the randomised trials. Lancet 365(9472):1687\u20131717. https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140673605665440\/abstract","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"7991_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ctrv.2016.09.019","volume":"50","author":"C Criscitiello","year":"2016","unstructured":"Criscitiello C, Esposito A, Trapani D, Curigliano G (2016) Prognostic and predictive value of tumor\u2013infiltrating lymphocytes in early breast cancer. Cancer Treat Rev 50:205\u2013207. https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.019","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"7991_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Cl\u00e9ment G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, Andr\u00e9 F, Kok M, Linn SC, Goetz MP, Michiels S (2024) International Immuno-Oncology Biomarker Working Group. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA 331(13):1135\u20131144. https:\/\/doi.org\/10.1001\/jama.2024.3056","journal-title":"JAMA"},{"issue":"2","key":"7991_CR34","first-page":"104120","volume":"10","author":"I Schlam","year":"2025","unstructured":"Schlam I, Loi S, Salgado R, Swain SM (2025) Tumor\u2013infiltrating lymphocytes in HER2\u2013positive breast cancer: potential impact and challenges. Breast Cancer Res 10(2):104120","journal-title":"Breast Cancer Res"},{"key":"7991_CR35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/modpathol.2016.231","volume":"30","author":"EM Yousef","year":"2017","unstructured":"Yousef EM, Furrer D, Laperriere DL, Tahir MR, Mader S, Diorio C, Gaboury LA (2017) MCM2: an alternative to Ki\u201367 for measuring breast cancer cell proliferation. Mod Pathol 30:682\u2013697","journal-title":"Mod Pathol"},{"issue":"7","key":"7991_CR36","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2020","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm A\u2013V, Pan H, Penault\u2013Llorca FM, Polley M\u2013Y, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF (2020) Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 113(7):808\u2013819. https:\/\/doi.org\/10.1093\/jnci\/djaa201","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07991-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:29:58Z","timestamp":1784017798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07991-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7991"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07991-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9029084\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients consented to participate in a observational IRB-approved registry protocol to collect their full health data retrospectively during the 5-year study period and biospecimens prospectively at the time of advanced breast cancer diagnosis. The specific analysis of the data in the registry for this study was further approved via a separate IRB-approved protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}